Nyxoah to attend upcoming investor conferences | 05.09.24

Nyxoah to attend upcoming investor conferences

Mont-Saint-Guibert, Belgium – September 5, 2024, 10:30 PM CET / 4:30 PM ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions for the treatment of obstructive sleep apnea (OSA), today announced that the Company will participate in three upcoming investor conferences in New York City.

Olivier Taelman, Chief Executive Officer of Nyxoah, will provide company updates at the Baird Global Healthcare Conference on Tuesday, September 10, 2024 at 12:15 p.m. ET, the HC Wainwright 26th Annual Global Investment Conference on Wednesday, September 11, 2024 at 11:00 a.m. ET, and the Cantor Global Healthcare Conference on Wednesday, September 18, 2024 at 1:55 p.m. Webcasts of the presentations will be available in the Events section of Nyxoah’s Investor Relations website. The company will also be available for 1×1 meetings with institutional investors attending the events.

Nyxoah’s Investor Presentation can be found in the Shareholder Information section of the company’s Investor Relations page.

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions for the treatment of obstructive sleep apnea (OSA). Nyxoah’s lead solution is the Genio® System, a patient-centric, leadless, battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep-related breathing disorder associated with increased mortality and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel empowered to live their lives to the fullest.

For more information, please refer to the Company’s fiscal year 2023 Annual Report or visit http://www.nyxoah.com/.

Caution – CE Marked since 2019. Investigational device in the United States. Restricted by U.S. Federal law to investigational use in the United States.

Forward-looking statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the current expectations of the Company or, as applicable, the Company’s directors or management with respect to the entering into of the Loan Agreement and the Synthetic Warrant Agreement with EIB; the use of proceeds from the Loan Agreement; the Genio® System and ongoing clinical studies of the Genio® System; the potential benefits of the Genio® System; Nyxoah’s goals with respect to the development, regulatory pathway and potential uses of the Genio® System; the utility of clinical data in potentially obtaining FDA clearance of the Genio® System; the reporting of data from Nyxoah’s DREAM US pivotal trial; the filing for FDA clearance; and entry into the U.S. market. Forward-looking statements, by their nature, involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. In addition, these risks and uncertainties include, but are not limited to, those set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2023 filed with the Securities and Exchange Commission (“SEC”) on March 20, 2024, and subsequent reports that the Company files with the SEC. A multitude of factors, including, but not limited to, changes in demand, competition and technology, could cause actual events, performance or results to differ materially from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations or warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or the officers or employees of any such person guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:

Nyxoah
Loïc Moreau, Financial Director
[email protected]

For media
Belgium/France
Backstage Communication – Gunther De Backer
[email protected]

International/Germany
MC Services – Anne Hennecke
[email protected]